Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,421 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 |
| clinicaltrials |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | terminated | Phase 2 | 13 | University of Southern CaliforniaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 1 | Emory UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00113919 | UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 14 | University of ArkansasOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT01646762 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Oct 16, 2017 | clinicaltrials |
| NCT00849251 | Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Sep 8, 2017 | clinicaltrials |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients | terminated | Phase 1 / Phase 2 | 18 | Tiziana MarangonOTHER | 1 | Sep 6, 2017 | clinicaltrials |
| NCT01720043 | Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients | terminated | Phase 2 | 8 | University of UtahOTHER | 1 | Sep 5, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | terminated | Phase 2 | 13 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00843310 | Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma | terminated | Phase 2 | 8 | NYU Langone HealthOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT01548573 | Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | terminated | Phase 2 | 19 | University of IowaOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01965834 | Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma | terminated | Phase 2 | 6 | University of MiamiOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT | terminated | Phase 2 | 4 | Mayo ClinicOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00676806 | A Phase II Study of Umbilical Cord Blood Transplantation | terminated | Phase 2 | 7 | Tufts Medical CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01729338 | Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 17 | Duke UniversityOTHER | 1 | May 31, 2017 | clinicaltrials |
| NCT00681044 | HD Melphalan and SCT in Patients With IGDD or LCDD | terminated | Phase 2 | 5 | Boston Medical CenterOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT00109889 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | terminated | Phase 2 | 2 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 24, 2017 | clinicaltrials |
| NCT01534143 | High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 1 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT01207765 | Zevalin for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma | terminated | Phase 2 | 8 | Tufts Medical CenterOTHER | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01484314 | Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma | terminated | Phase 2 | 1 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 15, 2017 | clinicaltrials |
| NCT02254551 | Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SCRI Development Innovations, LLCOTHER | 1 | Feb 16, 2017 | clinicaltrials |
| NCT00075608 | 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis | terminated | Phase 2 | 12 | Boston Medical CenterOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT01695330 | Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens | terminated | Phase 2 | 5 | OncotherapeuticsINDUSTRY | 1 | Jan 16, 2017 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | terminated | Phase 2 | 58 | Henrik GregersenOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | Jagannath, Sundar, M.D.INDIV | 1 | Jul 22, 2016 | clinicaltrials |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | terminated | Phase 2 | 17 | University of UtahOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT01023880 | Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy | terminated | Phase 1 / Phase 2 | 62 | CephalonINDUSTRY | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | terminated | Phase 1 / Phase 2 | 3 | Singapore General HospitalOTHER | 1 | Nov 30, 2015 | clinicaltrials |
| NCT00431340 | A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | terminated | Phase 2 | 4 | Valerio TherapeuticsINDUSTRY | 1 | Jul 8, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01653418 | Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation(V-BEAM) | terminated | Phase 2 | 10 | Washington University School of MedicineOTHER | 1 | Oct 15, 2014 | clinicaltrials |
| NCT00675428 | Study of Natalizumab in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 6 | BiogenINDUSTRY | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00240162 | PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma | terminated | Phase 2 | 21 | Washington University School of MedicineOTHER | 1 | Sep 17, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Dec 28, 2017source: clinicaltrials